DI-014 Efficacy and safety of fingolimod in patients with relapsing remitting multiple sclerosis

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Yearbook of Neurology and Neurosurgery ◽

10.1016/s0513-5117(09)79049-0 ◽

2009 ◽

Vol 2009 ◽

pp. 99-103

Author(s):

O. Kantarci

Keyword(s):

Multiple Sclerosis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Efficacy and safety of 2 doses of ponesimod (10 and 20 mg o.d.): Interim analysis of a phase II extension trial in relapsing-remitting multiple sclerosis

10.26226/morressier.59a3edabd462b8028d8951c5 ◽

2017 ◽

Author(s):

Eva Havrdova

Keyword(s):

Multiple Sclerosis ◽

Phase Ii ◽

Interim Analysis ◽

Efficacy And Safety ◽

Relapsing Remitting ◽

Relapsing Remitting Multiple Sclerosis ◽

Extension Trial

MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)

Case Medical Research ◽

10.31525/ct1-nct03846219 ◽

2000 ◽

Author(s):

Keyword(s):

Multiple Sclerosis ◽

Efficacy And Safety ◽

Relapsing Remitting ◽

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience

Therapeutic Advances in Neurological Disorders ◽

10.1177/1756286418796404 ◽

2018 ◽

Vol 11 ◽

pp. 175628641879640 ◽

Cited By ~ 6

Author(s):

Emanuele D’Amico ◽

Aurora Zanghì ◽

Graziella Callari ◽

Giovanna Borriello ◽

Antonio Gallo ◽

...

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Comparable Efficacy ◽

Real Word ◽

Efficacy And Safety ◽

Relapsing Remitting ◽

Efficacy and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis with a Suboptimal Response to Previous Disease-Modifying Therapies (1-Year Interim Results)

Multiple Sclerosis and Related Disorders ◽

10.1016/j.msard.2019.11.063 ◽

2020 ◽

Vol 37 ◽

pp. 101588

Author(s):

Patrick Vermersch ◽

Juha-Pekka Erälinna ◽

Richard Nicholas ◽

Celia Oreja-Guevara ◽

Aksel Siva ◽

...

Keyword(s):

Multiple Sclerosis ◽

Efficacy And Safety ◽

Disease Modifying Therapies ◽

Relapsing Remitting ◽

Disease Modifying ◽

Relapsing Remitting Multiple Sclerosis ◽

Previous Disease

Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis

CNS Drugs ◽

10.1007/s40263-019-00691-7 ◽

2020 ◽

Vol 34 (1) ◽

pp. 65-92 ◽

Cited By ~ 3

Author(s):

Damiano Paolicelli ◽

Alessia Manni ◽

Antonio Iaffaldano ◽

Maria Trojano

Keyword(s):

Multiple Sclerosis ◽

Efficacy And Safety ◽

Relapsing Remitting ◽

PND9 Comparative Efficacy and Safety of Ozanimod Versus Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A Matching-Adjusted Indirect Comparison

Value in Health ◽

10.1016/j.jval.2020.08.1334 ◽

2020 ◽

Vol 23 ◽

pp. S624

Author(s):

S. Cohan ◽

J. Kumar ◽

S. Arndorfer ◽

X. Zhu ◽

M. Zivkovic ◽

...

Keyword(s):

Multiple Sclerosis ◽

Indirect Comparison ◽

Efficacy And Safety ◽

Comparative Efficacy ◽

Relapsing Remitting ◽

Adjusted Indirect Comparison ◽

Efficacy and safety of delayed-release dimethyl fumarate in treatment-naïve Japanese patients with relapsing-remitting multiple sclerosis: A post-hoc subgroup analysis of the apex study

Journal of the Neurological Sciences ◽

10.1016/j.jns.2017.08.2241 ◽

2017 ◽

Vol 381 ◽

pp. 795-796

Author(s):

M. Mori ◽

T. Ohashi ◽

Y. Onizuka ◽

K. Hiramatsu ◽

M. Hase ◽

...

Keyword(s):

Multiple Sclerosis ◽

Subgroup Analysis ◽

Japanese Patients ◽

Dimethyl Fumarate ◽

Efficacy And Safety ◽

Relapsing Remitting ◽

Treatment Naïve ◽

Post Hoc ◽

Efficacy and safety of Alemtuzumab in treatment-naive patients with relapsing-remitting multiple sclerosis: Four-year follow-up of the Care-MS I study

Multiple Sclerosis and Related Disorders ◽

10.1016/j.msard.2014.09.207 ◽

2014 ◽

Vol 3 (6) ◽

pp. 761-762 ◽

Cited By ~ 2

Author(s):

X. Montalban ◽

J.S. Inshasi ◽

A.J. Coles ◽

H.P. Hartung ◽

E. Havrdova ◽

...

Keyword(s):

Multiple Sclerosis ◽

Efficacy And Safety ◽

Relapsing Remitting ◽

Treatment Naïve ◽

Long-Term Efficacy and Safety of Fingolimod (FTY720) in Relapsing-Remitting Multiple Sclerosis (RRMS): Results from the Extension of the Phase III FREEDOMS Study (S41.004)

Neurology ◽

10.1212/wnl.78.1_meetingabstracts.s41.004 ◽

2012 ◽

Vol 78 (Meeting Abstracts 1) ◽

pp. S41.004-S41.004 ◽

Cited By ~ 4

Author(s):

L. Kappos ◽

E.-W. Radue ◽

P. O'Connor ◽

C. Polman ◽

R. Hohlfeld ◽

...

Keyword(s):

Multiple Sclerosis ◽

Phase Iii ◽

Efficacy And Safety ◽

Term Efficacy ◽

Relapsing Remitting ◽